Pfizer Inc says its experimental COVID-19 vaccine is more than 90 percent effective, a major victory in the fight against a pandemic that has killed more than a million people, battered the world’s ...

Shares of German drug maker BioNTech SE rallied 24 per cent, while US-based Pfizer Inc. stock jumped over 14 per cent in pre-market trading on Monday after their COVID-19 vaccine candidate achieved ...

Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine ...

Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...

New 25-strain Prevnar candidate moves into final-stage testing after strong infant trial results against severe pneumonia strain.

For the second time in as many weeks, there is promising news from the race for a COVID-19 vaccine as infections surge across the United States and Europe. US biotech firm Moderna Inc on Monday said ...

Pfizer and Valenva are seeking regulatory approval from the Food and Drug Administration for a Lyme disease vaccine in development that's more than 70% effective against the tick-borne illness.

The phase 2 trial of the new vaccine – known as PF-07872412 or 25vPnC – revealed stronger immune responses to the serotypes ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.